The Danish biotechnology company Curasight announces that major shareholders have consolidated their holdings in a joint holding company, Curacap II, through an internal restructuring.Curacap II is jointly owned by co-founder Andreas Kjær and CEO Ulrich Krasilnikoff through their companies, with Peter Krasilnikoff also included as a co-owner. After the deal, Curacap II controls approximately 28 percent of shares and votes. The change does not affect the company's operations or financial position. After the deal, AK 2014 Holding owns approximately 54 percent of Curacap II, Krasilnikoff Holding 1 around 26 percent and Krasilnikoff Holding approximately 20 percent.